{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Famindr.com%2Fepisodes%2F334-treatments-targeting-neuroprotection-in-alzheimers-disease-pShR8b0b","width":444,"version":"1.0","type":"rich","title":"334 -Treatments Targeting Neuroprotection in Alzheimer's Disease","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/9a8ef428-72db-47cb-a5cb-a6a258a13785/e8b56d70-6b78-4097-a000-6c50f52d2b73/334-d4a-text.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/a4eedca6-ace3-48b2-bfcf-fbd385784f46\" height=\"200\" width=\"100%\" title=\"334 -Treatments Targeting Neuroprotection in Alzheimer&apos;s Disease\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Hello listeners, it’s been a while since we last released an episode but we are back with another series here at AMiNDR bringing you a synopsis of publications on Alzheimer’s disease (AD) research on various topics that were released in November of 2023. In this episode, Anusha takes you through 11 papers testing potential neuroprotective agents for AD treatment. You’ll hear about naturally and pharmaceutically-derived compounds as well as strategies that exploit cell-endogenous processes for neuroprotection in AD.\n\nTesting Naturally-Derived Compounds for Neuroprotective effects (3:53)\nTesting Cell-Endogenous Mechasims for Neuroprotection (16:57)\nTesting Pharmaceutically-Derived Compounds for Neuroprotective effects (20:17)\n"}